These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 34845071)

  • 1. Randomised controlled trial comparing rituximab to mycophenolate mofetil in children and young adults with steroid-dependent idiopathic nephrotic syndrome: study protocol.
    Lugani F; Angeletti A; Ravani P; Vivarelli M; Colucci M; Caridi G; Verrina E; Emma F; Ghiggeri GM
    BMJ Open; 2021 Nov; 11(11):e052450. PubMed ID: 34845071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol.
    Ravani P; Bonanni A; Ghiggeri GM
    BMJ Open; 2017 Mar; 7(3):e013319. PubMed ID: 28314744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized clinical trial to compare efficacy and safety of repeated courses of rituximab to single-course rituximab followed by maintenance mycophenolate-mofetil in children with steroid dependent nephrotic syndrome.
    Basu B; Preussler S; Sander A; Mahapatra TKS; Schaefer F
    BMC Nephrol; 2020 Nov; 21(1):520. PubMed ID: 33256621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
    Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
    BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial treatment of steroid-sensitive idiopathic nephrotic syndrome in children with mycophenolate mofetil
    Ehren R; Benz MR; Doetsch J; Fichtner A; Gellermann J; Haffner D; Höcker B; Hoyer PF; Kästner B; Kemper MJ; Konrad M; Luntz S; Querfeld U; Sander A; Toenshoff B; Weber LT;
    BMJ Open; 2018 Oct; 8(10):e024882. PubMed ID: 30309995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
    Liu ID; Willis NS; Craig JC; Hodson EM
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31749142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolate mofetil for sustained remission in nephrotic syndrome.
    Querfeld U; Weber LT
    Pediatr Nephrol; 2018 Dec; 33(12):2253-2265. PubMed ID: 29750317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome.
    Mendizábal S; Zamora I; Berbel O; Sanahuja MJ; Fuentes J; Simon J
    Pediatr Nephrol; 2005 Jul; 20(7):914-9. PubMed ID: 15891923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
    Hodson EM; Wong SC; Willis NS; Craig JC
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD003594. PubMed ID: 27726125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome.
    Sinha A; Gupta A; Kalaivani M; Hari P; Dinda AK; Bagga A
    Kidney Int; 2017 Jul; 92(1):248-257. PubMed ID: 28318625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial.
    Ravani P; Colucci M; Bruschi M; Vivarelli M; Cioni M; DiDonato A; Cravedi P; Lugani F; Antonini F; Prunotto M; Emma F; Angeletti A; Ghiggeri GM
    J Am Soc Nephrol; 2021 Oct; 32(10):2652-2663. PubMed ID: 34544820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome of Japanese children with complicated minimal change nephrotic syndrome treated with mycophenolate mofetil after cyclosporine.
    Fujinaga S; Hirano D; Nishino T; Umeda C; Watanabe Y; Nakagawa M
    Pediatr Nephrol; 2019 Nov; 34(11):2417-2421. PubMed ID: 31435725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome.
    Ravani P; Ponticelli A; Siciliano C; Fornoni A; Magnasco A; Sica F; Bodria M; Caridi G; Wei C; Belingheri M; Ghio L; Merscher-Gomez S; Edefonti A; Pasini A; Montini G; Murtas C; Wang X; Muruve D; Vaglio A; Martorana D; Pani A; Scolari F; Reiser J; Ghiggeri GM
    Kidney Int; 2013 Nov; 84(5):1025-33. PubMed ID: 23739238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of intravenous immunoglobulin with rituximab versus rituximab alone in childhood-onset steroid-dependent and frequently relapsing nephrotic syndrome: protocol for a multicentre randomised controlled trial.
    Hogan J; Perez A; Sellier-Leclerc AL; Vrillon I; Broux F; Nobili F; Harambat J; Bessenay L; Audard V; Faudeux C; Morin D; Pietrement C; Tellier S; Djeddi D; Eckart P; Lahoche A; Roussey-Kesler G; Ulinski T; Boyer O; Plaisier E; Cloarec S; Jolivot A; Guigonis V; Guilmin-Crepon S; Baudouin V; Dossier C; Deschênes G
    BMJ Open; 2020 Sep; 10(9):e037306. PubMed ID: 32967877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mycophenolate mofetil in treatment of childhood nephrotic syndrome--preliminary report].
    Kwinta-Rybicka J; Wilkosz K; Wierzchowska-Słowiacze EK; Ogarek I; Moczulska A; Stec Z; Pełkowska A; Sancewicz-Pach K; Pietrzyk JA
    Przegl Lek; 2006; 63 Suppl 3():44-8. PubMed ID: 16898486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized controlled trial to compare safety and efficacy of mycophenolate vs. cyclosporine after rituximab in children with steroid-resistant nephrotic syndrome.
    Assadi F; Mazaheri M; Sadeghi-Bodj S
    Pharmacotherapy; 2022 Sep; 42(9):690-696. PubMed ID: 35869690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protocol for an open-label, single-arm, multicentre clinical study to evaluate the efficacy and safety of rituximab in the first episode of paediatric idiopathic nephrotic syndrome.
    Liu J; Shen Q; Xie L; Wang J; Li Y; Chen J; Fang X; Tang X; Qian B; Xu H
    BMJ Open; 2022 Oct; 12(10):e064216. PubMed ID: 36223961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolate Mofetil after Rituximab for Childhood-Onset Complicated Frequently-Relapsing or Steroid-Dependent Nephrotic Syndrome.
    Iijima K; Sako M; Oba M; Tanaka S; Hamada R; Sakai T; Ohwada Y; Ninchoji T; Yamamura T; Machida H; Shima Y; Tanaka R; Kaito H; Araki Y; Morohashi T; Kumagai N; Gotoh Y; Ikezumi Y; Kubota T; Kamei K; Fujita N; Ohtsuka Y; Okamoto T; Yamada T; Tanaka E; Shimizu M; Horinochi T; Konishi A; Omori T; Nakanishi K; Ishikura K; Ito S; Nakamura H; Nozu K;
    J Am Soc Nephrol; 2022 Feb; 33(2):401-419. PubMed ID: 34880074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mycophenolate mofetil (MMF) as the first choice immunosuppressive drug in treatment of steroid-dependent nephrotic syndrome in children].
    Ogarek I; Szczęsny-Choruz E; Wierzchowska-Słowiaczek E; Kwinta-Rybicka J; Stec Z; Moczulska A; Wilkosz K; Drożdż D
    Pol Merkur Lekarski; 2018 Apr; 44(262):192-195. PubMed ID: 29775447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial.
    Scolari F; Dallera N; Gesualdo L; Santoro D; Pani A; Santostefano M; Feriozzi S; Mani LY; Boscutti G; Messa P; Magistroni R; Quaglia M; Ponticelli C; Ravani P
    BMJ Open; 2019 Dec; 9(12):e029232. PubMed ID: 31806605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.